Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer-Reference-Cited by-同舟云学术

Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer

Published:2023-09 Issue:34 Volume:29 Page:2684-2691
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Keyvani Vahideh¹²³,Mollazadeh Samaneh⁴,Kheradmand Nahid¹,Mahmoudian Reihaneh Alsadat³⁵⁶,Avan Amir³⁷⁸,Anvari Kazem⁹

Affiliation:

1. Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2. Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4. Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran

5. Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

6. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

7. College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq

8. School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT), Brisbane 4059, Australia

9. Department of Radiotherapy Oncology, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Abstract: Prostate cancer (PC) is identified as a heterogeneous disease. About 20 to 30% of PC patients experience cancer recurrence, characterized by an increase in the antigen termed serum prostate-specific antigen (PSA). Clinical recurrence of PC commonly occurs after five years. Metastatic castration-resistant prostate cancer (mCRPC) has an intricate genomic background. Therapies that target genomic changes in DNA repair signaling pathways have been progressively approved in the clinic. Innovative therapies like targeting signaling pathways, bone niche, immune checkpoint, and epigenetic marks have been gaining promising results for better management of PC cases with bone metastasis. This review article summarizes the recent consideration of the molecular mechanisms and signaling pathways involved in local and metastatic prostate cancer, highlighting the clinical insinuations of the novel understanding.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference94 articles.

1. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249

2. Giridharan M.; Rupani V.; Banerjee S.; Signaling pathways and targeted therapies for stem cells in prostate cancer. ACS Pharmacol Transl Sci 2022,5(4),193-206

3. Steele CB; Li J; Huang B; Weir HK; Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer 2017,123(S24),5160-5177

4. Jemal A.; Fedewa S.A.; Ma J.; Siegel R.; Lin C.C.; Brawley O.; Ward E.M.; Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015,314(19),2054-2061

5. Miller K.D.; Siegel R.L.; Lin C.C.; Mariotto A.B.; Kramer J.L.; Rowland J.H.; Stein K.D.; Alteri R.; Jemal A.; Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016,66(4),271-289